|
HS Code |
669343 |
| Name | Benzbromarone |
| Chemical Formula | C17H12Br2O3 |
| Molecular Weight | 424.09 g/mol |
| Appearance | White to off-white crystalline powder |
| Cas Number | 3562-84-3 |
| Atc Code | M04AB03 |
| Mechanism Of Action | Uricosuric agent; inhibits renal tubular reabsorption of uric acid |
| Therapeutic Use | Treatment of gout and hyperuricemia |
| Route Of Administration | Oral |
| Solubility | Practically insoluble in water |
| Melting Point | 146-148°C |
| Storage Conditions | Store at room temperature, protected from light and moisture |
As an accredited Benzbromarone factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | A 25-gram amber glass bottle labeled “Benzbromarone,” featuring hazard warnings, batch number, CAS number, and secure screw cap closure. |
| Shipping | Benzbromarone is shipped in accordance with international regulations for hazardous chemicals. It is packaged in secure, airtight containers to prevent leakage and contamination. The shipment includes appropriate labeling and documentation for safe handling and transportation. Specialized carriers are used to ensure compliance with temperature and safety requirements during transit. |
| Storage | Benzbromarone should be stored in a tightly closed container, protected from light and moisture. It should be kept at room temperature, ideally between 15–30°C (59–86°F). Store in a well-ventilated area away from incompatible substances such as strong oxidizing agents. Ensure the storage area is secure and clearly labeled to prevent unauthorized access or accidental exposure. |
|
Purity 99%: Benzbromarone with purity 99% is used in pharmaceutical formulations for managing chronic gout, where it ensures high efficacy in serum uric acid reduction. Melting point 140°C: Benzbromarone with a melting point of 140°C is used in oral tablet production, where it contributes to stable dosage forms during manufacturing. Molecular weight 424.1 g/mol: Benzbromarone with molecular weight 424.1 g/mol is used in clinical research applications, where it allows for accurate dosing and pharmacokinetic modeling. Particle size <50 µm: Benzbromarone with particle size less than 50 µm is used in micronized drug formulations, where it enhances dissolution rates and bioavailability. Stability temperature 25°C: Benzbromarone at stability temperature 25°C is applied in medicinal storage, where it maintains chemical integrity and prevents degradation. Solubility in ethanol 10 mg/mL: Benzbromarone with solubility in ethanol at 10 mg/mL is utilized in solution-based drug delivery, where it enables efficient compound dispersion. Residual solvent <0.1%: Benzbromarone with residual solvent below 0.1% is employed in GMP pharmaceutical manufacture, where it minimizes toxicological risks and meets safety standards. Assay ≥98%: Benzbromarone with assay greater than or equal to 98% is deployed in active pharmaceutical ingredient (API) supply, where it ensures consistent therapeutic outcomes. Moisture content <0.5%: Benzbromarone with moisture content less than 0.5% is used in long-term bulk storage, where it reduces hydrolysis and preserves product stability. Heavy metals <10 ppm: Benzbromarone with heavy metals content less than 10 ppm is utilized in regulated drug synthesis, where it complies with pharmacopeial safety requirements. |
Competitive Benzbromarone prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Anyone who’s ever suffered from gout knows just how urgent pain relief can feel. The swollen joints, the intrusive ache — they become a daily interference that’s hard to ignore. In the search for an answer, doctors and patients often turn to medicines like Benzbromarone. It isn’t as famous as some other gout treatments, yet this product has quietly built a reputation among those who need to keep uric acid levels in check. Through personal experience and careful study, Benzbromarone stands out for its specific approach to treating chronic gout, addressing the foundation of the problem rather than simply dulling the pain.
Benzbromarone works by helping the body pass more uric acid through urine. This isn’t just a small detail; the medicine’s main task is to give the kidneys a nudge, encouraging them to filter out excess uric acid that would otherwise gather in the joints. Compared with the more common gout medication allopurinol, which blocks uric acid production, Benzbromarone’s method focuses more on removing what’s already there. For people who can’t take first-line drugs due to allergies, stubborn side effects, or worse, repeated flare-ups that leave them out of options, this kind of difference can dramatically change their daily lives.
Not everyone realizes that certain medications recommended for one person may not fit another. I’ve talked to many patients who find themselves frustrated or lost after a string of ineffective prescriptions. Medical research supports that about ten percent of people with gout can’t properly use drugs that block uric acid production. Benzbromarone provides a crucial alternative here. Its main model, offered as an oral tablet, gives flexibility and simplicity in daily routines, especially for patients who may struggle to stick with complex regimens. When so much of gout treatment comes down to consistency and avoiding flare-ups, this straightforward approach offers comfort.
Doctors often recommend Benzbromarone only after seeing that other treatments like allopurinol or febuxostat aren’t working well, or when side effects push patients to search for something else. There’s trust built into such recommendations. Many physicians feel confident prescribing Benzbromarone to adults with chronic gout who consistently show high uric acid levels, especially in cases where kidney function remains stable. This matters in real life. Many other uricosuric agents simply don’t work if the kidneys aren’t up to the task, so Benzbromarone’s ability to work even in patients with mild kidney trouble can make a significant difference.
The experience of taking Benzbromarone is straightforward. Most patients receive a small tablet, meant for daily use. Dosage depends on each individual’s uric acid measurements, but it usually begins at a lower amount before increasing based on doctor’s guidance and lab results. People often appreciate that this medicine blends into their routines without a lot of fuss. From talking to pharmacists and monitoring the research, the practical reality is that long-term success depends on understanding what makes Benzbromarone unique. It doesn’t play well with everyone. Patients who have a history of kidney stones, for example, need careful monitoring, as the medicine’s uric acid-clearing action can sometimes make stone formation more likely.
There’s also a need to keep an eye on liver health. Unlike some other uricosuric agents and even compared to allopurinol, Benzbromarone can affect liver enzymes. Blood tests become part of a regular schedule for patients using this drug. For many, this is a small trade-off compared to the agony of untreated gout, but it’s not something anyone should ignore.
Choosing a gout treatment isn’t just about what the research says or what the doctor writes on a prescription pad. In current practice, people usually see allopurinol or febuxostat as the first choices for long-term uric acid lowering. Both block the enzyme responsible for uric acid production. This works well for a majority, but not for everyone. When these options fall short, uricosuric drugs step up, and among them, Benzbromarone provides a robust response by directly influencing how much uric acid the kidneys flush out.
I recall several cases where someone kept getting painful flares despite the highest recommended dose of allopurinol. The transition to Benzbromarone often comes as both a relief and a surprise. The speed and extent of uric acid reduction surpass what most expect. Pharmaceutical studies indicate that Benzbromarone can reduce serum urate by about forty to fifty percent in those who respond, especially in individuals with so-called “underexcretion” of uric acid. Results like these feel empowering — people regain control over their mobility and daily activities.
It’s not just about numbers, though. Each drug brings its own baggage. Allopurinol allergy, though rare, often means a dead end for patients in certain parts of the world, especially in Southeast Asia, where severe reactions occur more frequently due to genetic factors. Febuxostat raises concerns due to potential links with cardiovascular risk. In these cases, Benzbromarone becomes something beyond a fallback — it’s a lifeline. Still, the experience comes with a caveat. The product isn’t available in every country. There are places, like the United States, where regulators pulled it from the market over historical concerns about liver injury, even though current research continues to support its use in other regions with careful screening.
Benzbromarone tablets usually come in strengths of around 50 to 100 mg, which makes it easy for doctors to adjust doses in a way that matches patient needs. The basic tablet doesn’t stand out for fancy coatings or special release mechanisms — it’s made for reliability and ease. Storage is simple; room temperature, away from excess heat or moisture. These characteristics make it easy to get from pharmacy to home, with minimal chance of spoilage or dosing error.
For a long time, I’ve seen confusion over whether Benzbromarone is a high-tech new solution. The truth is, it’s been around in clinical use since the 1970s, and it doesn’t rely on modern manufacturing gimmicks. While the formulation is basic, this also means the drug remains affordable for many people when compared with branded, newly-patented alternatives. Cost, especially for chronic illness, always casts a shadow over treatment choices. Families juggling bills will see value not just in the effectiveness of Benzbromarone, but in the relative lack of financial strain—another overlooked but real advantage.
Scientists have spent decades learning why some people keep having repeated gout attacks, even as they try to eat well and exercise. It turns out that almost ninety percent of people with gout actually don’t overproduce uric acid — their kidneys simply don’t remove enough. Benzbromarone answers this problem head-on by stopping the reabsorption of uric acid at a specific transport protein in the kidney. This practical, targeted approach has proven itself in head-to-head comparisons with other drug options.
In both clinical trials and real-world experience, Benzbromarone lowers uric acid levels in a way that often feels more reliable than probenecid, another classic uricosuric drug. The difference comes down to potency and predictability. Probenecid can lose its punch in patients with reduced kidney function, while Benzbromarone continues to work, provided kidney and liver health stay in good standing. This matters an awful lot to older adults, who tend to see gradual declines in kidney clearance over the years, and who make up the bulk of those living with gout.
People often overlook the sheer burden untreated gout imposes — the physical pain, the missed days of work, the creeping fear of joint damage. Benzbromarone, by offering one more avenue for lowering uric acid, helps keep joints healthy and daily routines manageable. It’s a case where newer does not always mean better; knowing about an old standby can open doors that otherwise seem closed.
Any prescription brings a list of potential risks, and Benzbromarone is no different. The main flag goes up around liver function. Modern guidelines agree on one point: monitor liver enzymes regularly, especially in the first few months after starting the medicine. I’ve seen practitioners insist on monthly checks initially, easing into longer spans between tests as everything stays steady. Most patients never see a problem, yet this simple step keeps them safer, catching rare but serious issues early before they cause trouble.
Kidney stones also enter the conversation. Because Benzbromarone speeds up uric acid clearance, crystals sometimes gather in the urinary tract. Doctors often counter this risk by making sure patients drink plenty of water and, at times, pairing Benzbromarone with medications that alkalinize urine. It’s not always convenient, but it works. Patients find that a little planning goes a long way to smooth the experience and limit interruptions to their lives.
Beyond these issues, there’s a daily-life perspective to consider. No one wants to stack up a long list of side effects when trying to fix one problem. While allopurinol sometimes brings skin rashes or allergic reactions, and febuxostat stirs worry for people with heart disease, Benzbromarone’s concerns stay focused on liver and kidney management. This clarity helps patients and practitioners weigh options honestly. Folks who’ve tried other gout drugs without luck often report greater peace with Benzbromarone — not because every worry disappears, but because they finally reclaim some control over their health.
Gout doesn’t only strike the elderly, although stories from older adults grab the most attention. I’ve met young professionals, athletes sidelined from their routines, and people midway through careers, all facing the abrupt pain and frustration of gout. The thread that runs through each story is the struggle to find a steady, reliable solution that fits the demands of everyday life. Benzbromarone enters the scene as both a tried-and-true intervention and a hope for those left outside standard options.
Reliable, accessible tablets aren’t the only factor at play. Support comes from healthcare teams – physicians, pharmacists, dietitians – all of whom bring their own experience and caution to the table. Because Benzbromarone isn’t a new discovery, doctors draw on years of accumulated know-how, passing on little tips that go far: checking in after the first few doses, adjusting food intake, watching for unexpected yellowing of the skin or urine color changes. Patients who develop this proactive connection with their care team adjust faster, worry less, and make better progress on the path to joint health.
It’s easy for people to think every gout medication feels about the same. From what I’ve seen and read, that’s rarely the case. Some drugs demand more attention to meal timing; Benzbromarone typically does not. Others interact with a laundry list of other medications. Benzbromarone still asks for a bit of caution – people who use certain anticoagulants or anti-diabetes drugs need coordination to reduce risk – but the overall interaction list remains manageable by comparison.
Practicalities like cost, ease of finding the medicine, and frequency of use make a difference, especially for folks balancing more than one health condition. With Benzbromarone, simplicity becomes a real asset. The tablets serve a specific role and don’t require constant changes or complicated meal schedules. There’s also transparency in how outcomes get measured: uric acid blood levels tell the story, making progress clear and action steps easier to follow.
The decision to use Benzbromarone rarely comes lightly. People often arrive at this choice after months or even years of trial and error. For them, knowing the differences – more robust uric acid removal for the so-called underexcretors, reliable tablet forms, and a defined set of risks – brings relief. It becomes easier to settle into a routine, trust the process, and return attention to the rest of life.
Treating gout well means acknowledging individual differences and matching treatment to underlying needs, rather than forcing every patient into the same solution. With Benzbromarone in the picture, practitioners expand their toolkit and sidestep some of the roadblocks that undermine long-term success.
One key step involves education — not just for doctors, but for patients who sometimes hear only about newer brand names and miss the solid history of Benzbromarone. Greater awareness gives people a chance to advocate for themselves, asking the right questions and keeping their health goals front and center. This approach strengthens outcomes because informed patients stick to their routines and catch problems sooner.
Healthcare systems and policymakers could also help by streamlining access to safe, reliable gout medications. Re-examining guidelines and approval pathways, updating them with the latest safety evidence, ensures that options like Benzbromarone stay available to those who benefit most. Supporting research into new ways to monitor liver safety, or developing combination pills that tackle multiple angles of uric acid control, draws on Benzbromarone’s strengths and opens doors for even more personalized care.
You can’t ignore the stories that come from the real world. I remember meeting a man in his early fifties, sidelined from coaching his daughter’s soccer team by relentless gout. He’d cycled through pill after pill, only to meet side effects or minimal improvement. Benzbromarone wasn’t a miracle cure, but once his routine stabilized, he returned to those weekend games — not overnight, but steadily, one practice at a time. His story matches hundreds more, where medicine wasn’t the main character, but simply allowed life to pick up where pain left off.
Doctors, too, see the benefits. In countries that allow Benzbromarone, many rheumatologists recommend it confidently for people who have hit dead ends with other drugs. They rely on the drug’s straightforward dosing and adjust as needed with lab monitoring. The medicine demands respect for potential risks, but the rewards often outweigh the drawbacks.
Families notice the impact. Caregivers talk about how less pain means more engagement at home, longer walks with grandchildren, and a cut in sleepless, ache-filled nights. For those living decades with gout, Benzbromarone represents not just another tablet, but a chance to reset expectations about what the future might hold.
A future where fewer people with gout fall through the cracks requires everyone involved to stay flexible and open-minded. Benzbromarone models this by filling a particular need with a focused, practical solution. Wider research continues to refine how the medicine fits different patient groups — exploring genetic testing to spot people at greater risk of liver complications, or identifying the best partners for combination therapy in difficult cases.
Community health outreach plays a part. More patients learn about uric acid targets, the need for regular checks, and simple tactics like hydration to guard against kidney stones. These efforts matter. Through education and easy communication, people see better results and fewer complications, regardless of which medicine finds its way into their routine.
Benzbromarone may work in the background, but its real-world effects ripple outwards. By widening the range of options for uric acid control, this product restores a sense of control to people who live each day with the challenges of gout. In the hands of informed patients and dedicated practitioners, Benzbromarone goes far beyond a simple tablet — it becomes a practical answer for living well, even in the face of chronic disease.